150 related articles for article (PubMed ID: 36601731)
1. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
2. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
3. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
[TBL] [Abstract][Full Text] [Related]
6. Grover's Disease in a Kidney Transplant Recipient.
Kirincich J; Lončarić D; Bukvić Mokos Z; Bašić-Jukić N
Acta Dermatovenerol Croat; 2019 Sep; 27(3):192-194. PubMed ID: 31542066
[TBL] [Abstract][Full Text] [Related]
7. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
8. Grover disease and bullous pemphigoid: a clinicopathological study of six cases.
Ellenbogen E; Geller S; Azrielant S; Zeeli T; Goldberg I; Schmidt E; Zillikens D; Mrowietz U; Sherman S; Mercer S; Didkovsky E; Hodak E; Sprecher E
Clin Exp Dermatol; 2019 Jul; 44(5):524-527. PubMed ID: 30264538
[TBL] [Abstract][Full Text] [Related]
9. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
Bruni M; Moar A; Schena D; Girolomoni G
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
[TBL] [Abstract][Full Text] [Related]
10. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
Palla AR; Smith E; Doll D
Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
[TBL] [Abstract][Full Text] [Related]
11. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
12. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
14. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
[TBL] [Abstract][Full Text] [Related]
15. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
16. Atypical Bullous Pemphigoid After Linagliptin Intake.
Dbouk S; Bazzi N; Saad WA; Toribio A; Habre M; Salloum A
Am J Case Rep; 2021 Sep; 22():e932356. PubMed ID: 34584063
[TBL] [Abstract][Full Text] [Related]
17. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.
Shah RR; Bhate C; Hernandez A; Ho CH
Dermatol Ther; 2022 May; 35(5):e15432. PubMed ID: 35266258
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
19. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
20. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
